CHARM, Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity

Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme
N M Hawkins, D Wang, J J V McMurray, M A Pfeffer, K Swedberg, C B Granger, S Yusuf, S J Pocock, J Östergren, E L Michelson, F G Dunn

Heart Jan 2007, 93 (1) 59-64; DOI: 10.1136/hrt.2005.083949

CLINICAL
- Cardiovascular medicine
  - Arrhythmias
    - Bradyarrhythmias and heart block (268)
    - Tachyarrhythmias (225)
  - Cardiomyopathy
    - Dilated cardiomyopathy (325)
    - Hypertrophic cardiomyopathy (388)
    - Restrictive cardiomyopathy (36)
  - Congenital heart disease (879)
  - Drugs: cardiovascular system (10086)
  - Echocardiography (2385)
  - Heart failure (620)
  - Hypertension (3363)
  - Interventional cardiology (3322)
  - Ischaemic heart disease
    - Acute coronary syndromes (3126)
    - Percutaneous intervention (1096)
    - Stable coronary heart disease (210)
  - Pacing and electrophysiology (295)
  - Valvar diseases
    - Aortic valve disease (513)
    - Mitral valve disease (275)
    - Right sided valvular heart disease (159)
  - Venous thromboembolism (572)
- Diagnostics
  - Clinical diagnostic tests (5281)
- Endocrinology
  - Diabetes (920)
  - Metabolic disorders (1160)
- Sport and exercise medicine (6)
NON-CLINICAL
- Communication
- Epidemiology (4620)
- Health policy (275)
- Healthcare improvement and patient safety
  - Hospital ratings
  - Surgical mortality
- Occupational and environmental medicine
  - Disease and health outcomes
    - Cardiovascular
- Smoking and tobacco
  - Environmental tobacco smoke
  - Health effects of tobacco use (31)
  - Smoking cessation (70)
  - Tobacco use (719)
Special collections
- Cardiology in Focus (55)
- Cochrane Corner (36)
- Guidelines, Recommendations and Consensus Statements (2)
- Image challenges (245)
- Press releases (114)
- Review articles (494)
- Education in Heart (796)
- Education in Heart
  - Acute cardiovascular care (14)
  - Acute coronary syndromes (79)
  - Arrhythmias (26)
  - Atrial fibrillation and flutter (7)
  - Cardiovascular prevention (17)
  - Chronic ischaemic heart disease (11)
  - Clinical pharmacology (9)
  - Congenital heart disease in adult patients (233)
  - Diseases of the aorta and trauma to the aorta and heart (2)
  - Genetics (2)
  - Heart failure (53)
  - History taking and clinical examination (8)
  - Infective endocarditis (2)
  - Invasive imaging: cardiac catheterization and angiography (12)
  - Myocardial disease (25)
  - Non-invasive imaging (43)
  - Oncology and the heart (1)
  - Pericardial disease (3)
  - Peripheral arterial disease
  - Physical activity and sport in primary and secondary prevention
  - Pregnancy & heart disease (4)
  - Pulmonary arterial hypertension (6)
  - Sudden cardiac death & resuscitation (4)
  - Syncope
  - The cardiac consult (2)
  - The electrocardiogram
  - Thromboembolic venous disease (2)
  - Valvular heart disease (113)
- Editor's choice (315)
- Open access (859)

Log in using your username and password

Main menu

Log in using your username and password

You are here

CHARM, Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity